Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9843014 | 0.81 | NPC1 (0.60) | TRPV1TRPV4NPSR1 | |
| SCHEMBL8597230 | 0.79 | NPC1 (0.56) | MEN1KMT2A | |
| SCHEMBL9842888 | 0.77 | TRPV1 (0.60) | TRPV1ABL1MEN1KMT2A | |
| SCHEMBL9842954 | 0.77 | NQO2 (0.54) | CA1CA2MEN1KMT2ACA12 | |
| SCHEMBL11435148 | 0.76 | TRPV1 (0.56) | TRPV1TRPV4MEN1KMT2ANPSR1 | |
| SCHEMBL9081513 | 0.76 | TRPV1 (0.50) | NAMPTTRPV1PRMT1MEN1KMT2A | |
| SCHEMBL8811207 | 0.76 | TP53 (0.54) | MEN1KMT2A | |
| SCHEMBL8808773 | 0.76 | MAPK1 (0.57) | NAMPTMEN1KMT2ANPSR1 | |
| SCHEMBL892704 | 0.75 | HTT (0.54) | NAMPTMEN1KMT2AHPGD | |
| SCHEMBL9842872 | 0.75 | HDAC3 (0.59) | NAMPTTRPV1CA1CA2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102489-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | SUGEN, INC. | 2004-05-27 | — | — | US | disclosed |
| US-6649635-B2 | For therapy of cancer | SUGEN, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20020065283-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | MCMAHON GERALD (US) | 2002-05-30 | — | — | US | disclosed |
| EP-1012150-A4 | HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS | SUGEN INC (US) | 2002-05-29 | — | — | EP | disclosed |
| US-6316479-B1 | ANTICANCER AGENTS | SUGEN, INC. | 2001-11-13 | — | — | US | disclosed |
| EP-1012150-A1 | HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS | Sugen, Inc. (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998052944-A1 | HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS | SUGEN, INC. (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065283-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | ABL1, ERBB2, PRKDC | KIF11 3763/4885NAMPT 3034/4885TRPV1 4496/4885 |
| US-20040102489-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | ABL1, ERBB2, PRKDC | KIF11 3763/4885NAMPT 3034/4885TRPV1 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.